Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

141. Eligibility for cardiac resynchronization therapy in patients hospitalized with heart failure Full Text available with Trip Pro

Eligibility for cardiac resynchronization therapy in patients hospitalized with heart failure Recent guidelines recommend cardiac resynchronization therapy (CRT) in mildly symptomatic heart failure (HF) but favour left bundle branch block (LBBB) morphology in patients with moderate QRS prolongation (120-150 ms). We defined how many patients hospitalized with HF fulfil these criteria.A single-centre retrospective cohort study of 363 consecutive patients hospitalized with HF (438 admissions (...) patients hospitalized with HF fulfil LVEF and QRS criteria for CRT, most having a Class I or IIa indication. However, a large proportion is ineligible owing to co-morbidities or requires medical optimization. Although uptake of CRT was reasonable, there remain opportunities for improvement.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure

142. Prospective evaluation of integrated device diagnostics for heart failure management: results of the TRIAGE‐HF study Full Text available with Trip Pro

Prospective evaluation of integrated device diagnostics for heart failure management: results of the TRIAGE‐HF study The primary aim of the TRIAGE-HF trial was to correlate cardiac implantable electronic device-generated heart failure risk status (HFRS) with signs, symptoms, and patient behaviours classically associated with worsening heart failure (HF).TRIAGE-HF enrolled 100 subjects with systolic HF implanted with a Medtronic high-performance device and followed up at three Canadian HF (...) data on the distribution of abnormal device parameters contributing to high HFRS. High HFRS has good predictive accuracy for patient-reported signs, symptoms, and behaviours associated with worsening HF status. As such, HFRS may be a useful tool for ambulatory HF monitoring to improve both patient-centred and health system level outcomes.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure

143. Acute heart failure management in the USA and Japan: overview of practice patterns and review of evidence Full Text available with Trip Pro

Acute heart failure management in the USA and Japan: overview of practice patterns and review of evidence Globally, acute heart failure (AHF) remains an ongoing public health issue with its prevalence and mortality increasing in the east and the west. Effective treatment strategies to stabilize AHF are important to alleviate clinical symptoms and to improve clinical outcomes. However, despite the progress in the management of stable and chronic heart failure, no single agent has been proven (...) to play a definitive role in the management of AHF. As a consequence, contemporary treatment strategies for patients with AHF vary greatly by region. This manuscript reviews the medical treatment options for AHF, with an emphasis on the differences between the treatment strategies in the USA and Japan. This information would provide a framework for clinicians to evaluate and manage patients with AHF and highlight the remaining questions to improve clinical outcomes.© 2018 The Authors. ESC Heart

2018 ESC heart failure

144. Actionable Metabolic Pathways in Heart Failure and Cancer—Lessons From Cancer Cell Metabolism Full Text available with Trip Pro

Actionable Metabolic Pathways in Heart Failure and Cancer—Lessons From Cancer Cell Metabolism Recent advances in cancer cell metabolism provide unprecedented opportunities for a new understanding of heart metabolism and may offer new approaches for the treatment of heart failure. Key questions driving the cancer field to understand how tumor cells reprogram metabolism and to benefit tumorigenesis are also applicable to the heart. Recent experimental and conceptual advances in cancer cell (...) metabolism provide the cardiovascular field with the unique opportunity to target metabolism. This review compares cancer cell metabolism and cardiac metabolism with an emphasis on strategies of cellular adaptation, and how to exploit metabolic changes for therapeutic benefit.

2018 Frontiers in cardiovascular medicine

145. Sex, drugs, and heart failure: a sex‐sensitive review of the evidence base behind current heart failure clinical guidelines Full Text available with Trip Pro

Sex, drugs, and heart failure: a sex‐sensitive review of the evidence base behind current heart failure clinical guidelines Heart failure (HF) is a complex disease, almost as common in women as in men. Nonetheless, HF clinical presentation, prognosis, and aetiology vary by sex. This review summarizes the current state of sex-sensitive issues related to HF drugs included in treatment guidelines and suggests future directions for improved care. Heart failure presentation differs between female (...) , such as torsade de pointes and angiotensin-converting enzyme inhibitor-induced cough, occur more frequently in women, we emphasize the need to test medications thoroughly in both sexes and explore sexual dimorphisms. To better represent all of the targeted patient population and provide better care for all, two kinds of change must come about: recruitment methods to randomized clinical trial samples need to evolve and the participation needs to seem more attractive to women.© 2018 The Authors. ESC Heart

2018 ESC heart failure

146. Echocardiographic predictors of change in renal function with intravenous diuresis for decompensated heart failure Full Text available with Trip Pro

Echocardiographic predictors of change in renal function with intravenous diuresis for decompensated heart failure The aim of this study was to identify echocardiographic predictors of improved or worsening renal function during intravenous diuresis for decompensated heart failure. Secondary aim included defining the incidence and clinical risk factors for acute changes in renal function with decongestion.A retrospective review of 363 patients admitted to a single centre for decompensated heart (...) admitted with decompensated heart failure. WRF was statistically more likely in patients with a preserved left ventricular ejection fraction. A trend towards IRF was noted in patients with global right ventricular dysfunction.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure

147. Prospective assessment of combined handgrip strength and Mini‐Cog identifies hospitalized heart failure patients at increased post‐hospitalization risk Full Text available with Trip Pro

Prospective assessment of combined handgrip strength and Mini‐Cog identifies hospitalized heart failure patients at increased post‐hospitalization risk The utility of combined assessment of both frailty and cognitive impairment in hospitalized heart failure (HF) patients for incremental post-discharge risk stratification, using handgrip strength and Mini-Cog as feasible representative parameters, was investigated.A prospective, single-centre cohort study of older adults (age ≥65 (...) impaired according to severely reduced Mini-Cog performance show the worst midterm post-discharge outcomes after HF hospitalization.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure

148. Daily non‐invasive haemodynamic telemonitoring for efficacy evaluation of MitraClip® implantation in patients with advanced systolic heart failure Full Text available with Trip Pro

in PAP values in patients after MitraClip with PAP changes in patients without MitraClip.Among 28 patients with New York Heart Association III heart failure with implanted PAP sensor for haemodynamic telemonitoring from a single centre, four patients (age 66 ± 6 years, left ventricular ejection fraction 21 ± 3%, and cardiac index 1.8 ± 0.3) received a MitraClip procedure and were compared with 24 patients (age 72 ± 8 years, left ventricular ejection fraction 26 ± 9.9%, and cardiac index 2.0 ± 1.0 (...) Daily non‐invasive haemodynamic telemonitoring for efficacy evaluation of MitraClip® implantation in patients with advanced systolic heart failure Patients with advanced systolic chronic heart failure frequently suffer from progressive functional mitral regurgitation. We report our initial experience in patients with an implanted pulmonary artery pressure (PAP) sensor, who developed severe mitral regurgitation, which was treated with the MitraClip system. We non-invasively compared changes

2018 ESC heart failure

149. Heart Failure. (Abstract)

Heart Failure. Heart failure affects more than 6 million people in the United States and incurs a heavy toll in morbidity, mortality, and health care costs. It frequently coexists with other important disorders, including hypertension, coronary artery disease, diabetes, and obesity. Decades of clinical trials have shown that several medications and interventions are effective for improving outcomes; however, mortality and hospitalization rates remain high. More recently, additional medications (...) and devices have shown promise in reducing the health burden of heart failure.

2018 Annals of Internal Medicine

150. Treatment of Atrial Fibrillation in Patients with Co-existing Heart Failure and Reduced Ejection Fraction: Time to Revisit the Management Guidelines? Full Text available with Trip Pro

Treatment of Atrial Fibrillation in Patients with Co-existing Heart Failure and Reduced Ejection Fraction: Time to Revisit the Management Guidelines? AF in patients with heart failure and reduced ejection fraction (HFrEF) is common and is associated with an increased risk of stroke, heart failure hospitalisation and all-cause mortality. Rhythm control of AF in this population has been traditionally limited to the use of antiarrhythmic drugs. Clinical trials assessing superiority

2018 Arrhythmia & electrophysiology review

151. Atrial Fibrillation Ablation in Patients with Heart Failure: One Size Does Not Fit All Full Text available with Trip Pro

Atrial Fibrillation Ablation in Patients with Heart Failure: One Size Does Not Fit All Atrial fibrillation (AF) is common in patients with heart failure and is associated with poorer clinical outcomes compared with patients with heart failure alone. Recent evidence has challenged previous treatment paradigms in which rate control was considered equivalent to rhythm control in this population. Catheter ablation has emerged as a safe and effective treatment strategy in selected patients (...) and overcomes the issues of limited efficacy and drug toxicities associated with pharmacological rhythm control. Numerous studies have explored the benefits of catheter ablation in patients with heart failure, but these have included heterogeneous patient cohorts and variable ablation strategies. This state-of-the-art review explores the evidence from these trials and examines the need for tailored, patient-specific strategies for AF ablation in patients with heart failure.

2018 Arrhythmia & electrophysiology review

152. His Bundle Pacing: A New Frontier in the Treatment of Heart Failure Full Text available with Trip Pro

His Bundle Pacing: A New Frontier in the Treatment of Heart Failure Biventricular pacing has revolutionised the treatment of heart failure in patients with sinus rhythm and left bundle branch block; however, left ventricular-lead placement is not always technically possible. Furthermore, biventricular pacing does not fully normalise ventricular activation and, therefore, the ventricular resynchronisation is imperfect. Right ventricular pacing for bradycardia may cause or worsen heart failure (...) in some patients by causing dyssynchronous ventricular activation. His bundle pacing activates the ventricles via the native His-Purkinje system, resulting in true physiological pacing, and, therefore, is a promising alternate site for pacing in bradycardia and traditional CRT indications in cases where it can overcome left bundle branch block. Furthermore, it may open up new indications for pacing therapy in heart failure, such as targeting patients with PR prolongation, but a narrow QRS duration

2018 Arrhythmia & electrophysiology review

153. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

2018 Circulation. 2018;137:e578–e622 You are viewing the most recent version of this article. Previous versions: Abstract Background and Purpose: The diverse causes of right-sided heart failure (RHF) include, among others, primary cardiomyopathies with right ventricular (RV) involvement, RV ischemia and infarction, volume loading caused by cardiac lesions associated with congenital heart disease and valvular pathologies, and pressure loading resulting from pulmonic stenosis or pulmonary (...) options and enhanced outcomes in patients with acute and chronic disorders of the right side of the heart. RV dysfunction (RVD), defined here as evidence of abnormal RV structure or function, is associated with poor clinical outcomes independently of the underlying mechanism of disease: across the spectrum of left ventricular (LV) ejection fraction (EF) in patients with acute and chronic heart failure (HF), after cardiac surgery, acute myocardial infarction (MI), congenital heart disease (CHD), and PH

2018 American Heart Association

154. Long‐term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin‐converting enzymes/angiotensin receptor blockers: results from AMETHYST‐DN Full Text available with Trip Pro

Long‐term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin‐converting enzymes/angiotensin receptor blockers: results from AMETHYST‐DN Chronic kidney disease (CKD) in heart failure (HF) increases the risk of hyperkalaemia (HK), limiting angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) use. Patiromer is a sodium-free, non-absorbed potassium binder approved for HK treatment. We (...) potassium. The most common patiromer-related adverse event was hypomagnesaemia (8.6%).In patients with a clinical diagnosis of HF, diabetes, CKD, and HK on ACE-I/ARB, patiromer was well tolerated and effective for HK treatment over 52 weeks.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure Controlled trial quality: uncertain

155. Effectiveness of a transition plan at discharge of patients hospitalized with heart failure: a before‐and‐after study Full Text available with Trip Pro

Effectiveness of a transition plan at discharge of patients hospitalized with heart failure: a before‐and‐after study We evaluated the effectiveness of a multidisciplinary transition plan to reduce early readmission among heart failure patients.We conducted a before-and-after study in a tertiary internal medicine department, comparing 3 years of retrospective data (pre-intervention) and 13 months of prospective data (intervention period). Intervention was the introduction in 2013 (...) of a transition plan performed by a multidisciplinary team. We included all consecutive patients hospitalized with symptomatic heart failure and discharged to home. The outcomes were the fraction of days spent in hospital because of readmission, based on the sum of all days spent in hospital, and the rate of readmission. The same measurements were used for those with potentially avoidable readmissions. Four hundred thirty-one patients were included and compared with 1441 patients in the pre-intervention

2018 ESC heart failure

156. Therapeutic implications of a combined diagnostic workup including endomyocardial biopsy in an all‐comer population of patients with heart failure: a retrospective analysis Full Text available with Trip Pro

Therapeutic implications of a combined diagnostic workup including endomyocardial biopsy in an all‐comer population of patients with heart failure: a retrospective analysis Aetiology of heart failure (HF) often remains obscure. We therefore evaluated the usefulness of a combined diagnostic approach including cardiac magnetic resonance imaging (CMRI) and endomyocardial biopsy (EMB) to assess the cause of unexplained cardiomyopathy underlying HF.We retrospectively investigated 100 consecutive (...) patients (36% women, mean age 53.6 ± 18.8 years) presenting with unexplained cardiomyopathy (HF with reduced ejection fraction or left ventricular hypertrophy; excluding ischaemic and valvular heart disease; left ventricular ejection fraction 31.6 ± 13.9%, Left ventricular end-diastolic pressure 18.2 ± 9.3 mmHg, heart rate 89 ± 26.6 b.p.m.; mean ± SEM) at the University Medical Center Mainz. We performed electrocardiography, echocardiography, CMRI, and cardiac catheterization with EMB analysed

2018 ESC heart failure

157. Ivabradine (Lancora) - chronic heart failure

Ivabradine (Lancora) - chronic heart failure Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2018 Health Canada - Drug and Health Product Register

158. Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure

”. The application was transferred to IQWiG on 27 November 2015. According to the applicant, the method applied – hereinafter referred to as “PA pressure monitoring” – aims to detect early haemodynamic changes in the pulmonary circulation of heart failure patients to help optimize drug treatment and avoid symptoms, cardiac decompensation and hospitalization. Results from a randomized controlled trial (RCT) were available for the method “measurement and monitoring of pulmonary artery pressure via an implanted (...) Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure 1 Translation of the executive summary of the assessment of potential Messung und Monitoring des pulmonalarteriellen Druckes mittels implantiertem Sensor zur Therapieoptimierung bei Herzinsuffizienz (Version 1.0; Status: 8 January 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

159. Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure ? Addendum to Commission E15-04

Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure ? Addendum to Commission E15-04 1 Translation of the executive summary of the addendum Messung und Monitoring des pulmonalarteriellen Druckes mittels implantiertem Sensor zur Therapieoptimierung bei Herzinsuffizienz – Addendum zum Auftrag E15-04 (Version 1.0; Status: 20 April 2016). Please note: This translation is provided as a service by IQWiG to English-language readers (...) . However, solely the German original text is absolutely authoritative and legally binding. Executive Summary IQWiG Reports – Commission No. E16-02 Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure – Addendum to Commission E15-04 1 Executive summary of Addendum E16-02 Version 1.0 PA pressure monitoring in heart failure 20 April 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

160. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality Full Text available with Trip Pro

NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality The concept of natriuretic peptide guidance has been extensively studied in patients with chronic heart failure (HF), with only limited success. The effect of NT-proBNP (N-terminal probrain natriuretic peptide)-guided therapy in patients (...) versus conventional patients, P=0.39). Guided therapy also did not significantly improve any of the secondary end points.The PRIMA II trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?) demonstrates that the guidance of HF therapy to reach an NT-proBNP reduction of >30% after clinical stabilization did not improve 6-month outcomes.URL: http://www.trialregister.nl. Unique identifier: NTR3279.© 2017 American Heart

2018 EvidenceUpdates